Overview of Papaverine HCl

Property	Description
Active ingredient	Papaverine hydrochloride
Form	Tablet, Capsule, Solution for Injection
Pharmacological class	Smooth Muscle Relaxant / Antispasmodic
Common use	Relief of spasms and improvement of circulation
Origin	Non-narcotic opium alkaloid derivative

What Type of Medicine is Papaverine HCl? (Identity and Classification)

Papaverine HCl (Papaverine hydrochloride) is a prescription-only medication (Rx) primarily classified as a non-specific smooth muscle relaxant and a direct-acting antispasmodic agent. The active ingredient is Papaverine, an isoquinoline derivative and historically a non-narcotic opium alkaloid. This chemical heritage is significant, as it confirms the substance's function is focused entirely on relaxing muscles without possessing the addictive properties associated with narcotic opioids. Its role as a spasmolytic agent is clinically recognized for its direct action on muscle tissues.

Papaverine HCl Composition and Forms (Structure and Availability)

The medicine is a single-ingredient product, differing from combination spasmolytics, where the active substance is the stable hydrochloride salt of Papaverine. This salt form enhances its utility for medicinal delivery. Papaverine HCl is supplied in multiple pharmaceutical preparations, including tablets and capsules for oral intake, as well as a sterile solution for injection for parenteral administration, and suppositories for rectal use. This versatility in form allows for different administration routes, depending on the speed of effect required.

What is the General Benefit of a Direct-Acting Antispasmodic? (High-Level Purpose)

The general benefit of Papaverine HCl arises from its unique ability to directly induce spasmolysis, the process of releasing or preventing the involuntary tightening of smooth muscles. This action results in vasodilation (widening of the vessels). This physiological effect is typically leveraged to address situations involving muscle tension and circulatory restriction. For example, it is used to alleviate internal cramping and improve blood flow, thereby reducing discomfort and restoring normal function where involuntary muscle contraction is a primary issue.

Regulatory References

FDA DailyMed Label for Papaverine HCl Injection

What side effects are possible with Papaverine HCl?

Possible Side Effects and Safety Information

The safety profile for Papaverine HCl covers a range of reactions, with emphasis on gastrointestinal, neurological, and cardiovascular effects, as well as specific warnings related to its administration.

Adverse Reactions Summary

System/Category	Common Reactions	Serious/Clinically Significant Reactions
Gastrointestinal	Nausea, constipation, diarrhea, loss of appetite, abdominal discomfort.	Hepatitis (infrequently reported, rarely progressing to cirrhosis).
Nervous System	Headache, drowsiness, dizziness, spinning sensation, general ill-feeling (malaise).	Sedation/sleepiness (with very large doses).
Cardiovascular	Increase in heart rate, slight rise in blood pressure, flushing, perspiration.	Transient ectopic rhythms of ventricular origin (premature beats or paroxysmal tachycardia) when injected intravenously with depressed conduction.
Other	Skin rash, fatigue, injection site reactions (pain, swelling, redness).	Priapism (painful, persistent erection) reported with intracorporeal use. Systemic allergic reactions (e.g., swelling of the face, throat).

Safety Restrictions and Monitoring

Contraindications include a known hypersensitivity to the drug and the presence of complete atrioventricular (AV) heart block for intravenous administration. The drug is not indicated for the treatment of impotence via intracorporeal injection due to the risk of persistent priapism requiring intervention.

Caution is advised in patients with glaucoma or those with depressed cardiac conduction. Monitoring is required; the medication must be discontinued if signs of hepatic hypersensitivity, such as gastrointestinal symptoms, jaundice (yellowing of the skin or eyes), or altered liver function test values, become evident. Safety and effectiveness in children have not been established. Use in pregnant women (Category C) and nursing mothers requires caution.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Papaverine hydrochloride (HCl) is documented in regulatory prescribing information and requires immediate medical attention. The manifestations reflect excessive action as a smooth muscle relaxant, affecting major physiological systems.

Documented Clinical Manifestations

Gastrointestinal Effects: Nausea, vomiting, and abdominal discomfort are documented signs.
Central Nervous System (CNS) Effects: Signs include drowsiness, weakness, lethargy, excessive sedation, and nystagmus (involuntary eye movements).
Cardiovascular Effects: Overdose may present with hypotension (low blood pressure) and tachycardia (fast heart rate).

Severe Outcomes and Required Actions

Severe outcomes officially listed in regulatory documents include life-threatening cardiac effects such as ventricular premature contractions and the potential for Torsades de Pointes. Extreme toxicity may also lead to respiratory depression and coma, along with reported hepatic function impairment.

Regulatory authorities mandate that individuals must seek immediate medical attention and contact a Poison Control Center for any suspected overdose. No specific antidote is known for Papaverine HCl. Management is therefore restricted to symptomatic and supportive treatment, with continuous Electrocardiogram (ECG) monitoring required for severe cases.

Therapeutic Uses of Papaverine HCl

Quick Facts

Primary domain: Addressing circulation problems and conditions associated with smooth muscle spasm.
Potential benefits: Helps promote improved blood flow and manage muscle constriction.
Therapeutic areas: Conditions involving the arteries, such as cerebral, coronary, and peripheral arterial concerns.

Papaverine HCl is an approved therapeutic option used to address poor circulation and manage conditions where smooth muscle spasm is a factor. Its mechanism involves helping to relax the smooth muscles in blood vessel walls, which in turn facilitates improved blood flow throughout the body.

This medication is primarily indicated for therapeutic domains concerning arterial function. These include helping to manage conditions associated with spasm of the coronary and cerebral arteries, as well as other circumstances of peripheral vascular disease where a spasm is evident. It is also used to manage the effects of certain embolisms in peripheral or pulmonary arteries.

Eligibility and Restrictions for Use

Who Can and Cannot Use Papaverine HCl? — Official Regulatory Information

Eligibility for Papaverine hydrochloride is defined by specific regulatory constraints, emphasizing contraindications and conditional use. The medicine is generally established for use in the adult population but has absolute restrictions for certain groups and scenarios.

Contraindications and Prohibited Uses

Restriction Category	Status	Details
Cardiovascular	Contraindicated	Prohibited for intravenous injection in patients with complete Atrioventricular (AV) heart block.
Hypersensitivity	Contraindicated	Patients with known allergy to Papaverine HCl or its components.
Specific Route	Prohibited	Must not be used for intracavernosal injection to treat impotence.

Conditional Use and Age Limitations

Pediatric Use: Safety and effectiveness have not been established in children.
Hepatic Status: Must be used with caution in patients with pre-existing liver disease (hepatic impairment). The medicine must be discontinued immediately if signs of hepatic hypersensitivity appear.
Glaucoma: Use requires caution.
Pregnancy/Lactation: Use during pregnancy is designated Category C and is allowed only if clearly needed. Caution is required during lactation as excretion into breast milk is unknown.

What should I know about interactions with other medicines?

Papaverine HCl Interactions with other medicines and products

The official regulatory profile for Papaverine HCl primarily documents interactions based on pharmacodynamic augmentation and specific procedural prohibitions.

Official Restrictions and Avoidance: Co-administration with Levodopa is restricted and should be avoided due to documented therapeutic interference that can worsen Parkinsonism. Similarly, the use of specific QTc-prolonging agents with Papaverine may increase the risk and severity of QTc prolongation, constituting a potential high-level interaction risk. Combining Papaverine with agents like Phentolamine or Alprostadil (for intracavernosal use) is not recommended.

Pharmacodynamic Augmentation: The product demonstrates additive effects with specific therapeutic categories. Co-administration with CNS depressants (including Morphine, sedatives, and hypnotics) may result in pharmacodynamic potentiation and enhanced sedation. The risk of hypotension may also be increased when taken alongside various antihypertensive agents.

Procedural and Substance Constraints: Papaverine HCl must not be added to Lactated Ringer's Injection or mixed with the contrast agent Ioxaglate due to documented physical incompatibility that results in precipitation. Consumption of alcohol or co-use of the herbal supplement Ginkgo can increase the risk of certain side effects, such as drowsiness and dizziness. An interaction-related caution specifies that co-use with anticoagulants via the intracavernosal route carries an increased propensity for bleeding at the injection site.

Mechanism of Action

Modulating Smooth Muscle Tension via Phosphodiesterase Inhibition

Papaverine HCl primarily functions as a non-selective inhibitor of phosphodiesterase (PDE) enzymes, which are responsible for breaking down the secondary messenger molecules, cyclic adenosine monophosphate ( cAMP) and cyclic guanosine monophosphate ( cGMP). By preventing their degradation, the drug elevates the intracellular concentration of these messengers. This increase initiates a cascade that inactivates Myosin Light-Chain Kinase ( MLCK), the enzyme essential for muscle fiber contraction. This action is the core mechanism resulting in spasmolysis (smooth muscle relaxation) across various systems.

Complementary Action Through Calcium Channel Interference

Complementing its enzymatic inhibition, Papaverine HCl also exerts a secondary mechanistic effect by acting as a modulator of voltage-gated Ca^2+ channels. This interference reduces the influx of calcium ions into the smooth muscle cell, further diminishing the critical signal required to initiate and sustain muscle contraction. The combined effect of elevated cyclic nucleotides and reduced calcium availability facilitates the sustained relaxed state of the muscle tissue. This dual mechanism produces the physiological outcome of widespread vasodilation and reduced visceral muscle tone.

Dosage and Administration Information

Papaverine HCl is administered through several approved routes, reflecting its varied clinical use patterns. The medicine is available for oral intake as a conventional tablet or an extended-release capsule, or for parenteral administration via intravenous (IV) or intramuscular (IM) injection.

The oral dosing regimen for the extended-release capsule typically begins at 150 mg taken every 12 hours, though upward adjustment to 300 mg every 12 hours may occur. These capsules are designated for sustained maintenance, and proper use requires that the dose be swallowed whole to preserve the intended release profile; the capsules must not be crushed or chewed. Generally, the oral forms may be administered without regard to meals.

Parenteral administration is reserved for acute, intermittent scenarios where an immediate physiological effect is desired. The usual adult dose for the injection solution ranges from 30 mg to 120 mg and may be repeated every three hours as required. Strict procedural conditions govern this route: Intravenous injection must be administered slowly over a duration of one to two minutes, and this procedure is generally required to take place under the immediate supervision of a physician.

The safety and effectiveness of Papaverine HCl have not been established for use in pediatric patients. Furthermore, for the injectable solution, specialized handling instructions prohibit mixing the drug with certain IV solutions, such as Lactated Ringer’s Injection, due to chemical compatibility concerns.

Recent Clinical Evidence

Evidence for Use in Arterial Ischemia and Vasospasm

Research has studied this compound in contexts related to conditions characterized by fluctuating or episodic manifestations of arterial restriction, such as cerebral or peripheral vasospasm. The evidence base here largely includes older comparative trials and subsequent retrospective analyses that monitored outcomes related to systemic or functional imbalance, including measurements of blood flow and the change in symptom presentation.

The research highlights changes measured during the study period, which were observed during the acute or intra-procedural phase of treatment. Certainty remains low for this broad indication because the evidence is often derived from older studies. Long-term effects are not fully established, and there is a recognized lack of significant, large-scale randomized controlled trials (RCTs).

Evidence for Use in Acute Procedural Spasm Prevention

Research here includes active and completed Randomized Controlled Trials (RCTs) and various procedural analyses focused on its application for the study of involuntary smooth muscle contractions during certain medical procedures. These studies monitored outcomes related to physical discomfort, primarily focusing on procedural success rates and the incidence of artery spasm in adults undergoing these interventions. Trials reported how symptoms evolved in the observed populations over acutely time-bound periods, typically minutes to a few hours.

Evidence for Use in Managing Visceral Smooth Muscle Spasm

Research has explored this compound’s application in managing conditions involving periods of heightened symptoms related to involuntary smooth muscle contraction in various organ systems (e.g., renal colic, labor). Studies examined outcomes reflecting episodic or acute changes, such as measurements of pain reduction (using patient-reported outcomes) and functional/procedural endpoints, such as measurements related to the duration of labor. The findings describe patterns observed in the studies that were consistently short-term.

What is Still Uncertain About the Research for Papaverine HCl

The available evidence for most indications is limited to studies observing patterns over defined time intervals that rarely extend beyond the acute phase of care. A key limitation relates to the reliance on older studies for traditional indications that do not meet modern standards for trial evaluation, and the small sample sizes found in some of the newer comparative trials. Long-term effects are not fully established. These research gaps highlight the need for continued, high-quality controlled studies. Research provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Papaverine HCl (FAQ)

Q: What conditions is Papaverine HCl primarily used to treat?

Regulatory documents indicate that Papaverine is used to help improve blood flow in patients who experience issues with circulation. It is also used for the relief of involuntary tightening or spasm of various smooth muscles. Specific conditions that may involve such spasms include those affecting cerebral and peripheral arteries, as well as smooth muscle in the internal organs.

Q: How quickly does Papaverine HCl start to work when injected?

According to official product information, the injectable form is typically reserved for scenarios where an immediate physiological effect is desired. This indicates a fast onset of action is generally expected, although regulatory text does not provide a specific timeframe for its effect.

Q: Is Papaverine HCl related to the opium poppy, and if so, is it addictive?

Papaverine is derived from the opium poppy but is classified as a non-narcotic opium alkaloid. Unlike narcotic opioids, official sources confirm its function is primarily focused on relaxing muscles and that it is non-addictive.

Q: Can Papaverine HCl be used for issues other than circulation problems?

Yes, official information indicates that Papaverine is a general smooth muscle relaxant and antispasmodic. Its use has been studied in conditions involving visceral smooth muscle spasm, which relates to the involuntary tightening of muscles found in internal organs, not only in blood vessels.

Q: Are there any long-term side effects associated with Papaverine HCl use?

Official regulatory texts list the known common and serious side effects, which mostly relate to short-term use. The evidence base for long-term effects for many traditional indications is officially noted as not fully established, meaning long-term effects for many traditional indications are not fully understood.

Q: Can patients with glaucoma use Papaverine HCl?

Official product information specifies that Papaverine should be used with caution in patients with glaucoma. Caution is required and typically involves medical supervision.

Q: Is Papaverine HCl available in different forms, like tablets, injections, or creams?

Official regulatory sources state that Papaverine HCl is supplied as tablets, capsules, a solution for injection, and suppositories. Compounded creams are not listed among the officially approved pharmaceutical forms.

Q: Can the effectiveness of Papaverine HCl decrease over time (tolerance)?

Some literature related to specialized and long-term uses suggests that a potential for reduced response, known as tolerance, may occur over an extended period. The potential for reduced response (tolerance) has been noted for certain long-term applications, such as intracavernosal injection.

Q: Does Papaverine HCl help with muscle spasms in areas other than blood vessels?

Yes. Official regulatory classifications describe Papaverine as a smooth muscle relaxant and antispasmodic agent. This means its primary action is to relax involuntary muscle tissue in various organs, including, but not limited to, the smooth muscle surrounding blood vessels.

Q: Does consuming alcohol interact with Papaverine HCl?

Official product labeling advises that consumption of alcohol can increase the risk of certain side effects while taking Papaverine HCl. These potential side effects include increased drowsiness and dizziness.

Q: Are there any known food or supplement interactions with Papaverine HCl?

Regulatory information advises caution regarding certain supplements. Co-use of the herbal supplement Ginkgo can increase the risk of side effects such as drowsiness and dizziness. No specific interactions with common foods are noted in the official product information.

Q: Can Papaverine HCl be used in older patients?

The use of Papaverine HCl is generally established for the adult population. While specific comparative data for the elderly are limited, general external references state the medicine is not expected to cause different side effects or problems in older people than it does in younger adults.

Q: Is Papaverine HCl ever prescribed to children?

Official regulatory information specifies that the safety and effectiveness of Papaverine HCl have not been established in children. This statement is based on the fact that safety and effectiveness have not been established in children.

Q: Why is Papaverine HCl used in some surgical procedures?

Studies and official information indicate that the drug is used in contexts related to Acute Procedural Spasm Prevention. Its use is focused on reducing the incidence of artery spasm in adult patients undergoing certain interventions, and is studied in relation to improving procedural outcomes.

Q: Can Papaverine HCl cause a change in vision?

While a change in vision is not listed as a common side effect, the medication does require caution in patients with glaucoma. Additionally, symptoms of a very large overdose may include diplopia (double vision) and nystagmus (involuntary eye movements).

Q: Are there any specific monitoring tests required while using Papaverine HCl?

Official warnings state that if signs of hepatic hypersensitivity (severe liver reaction) appear, the medication must be discontinued, and monitoring of liver function test values may be initiated. Periodic evaluations of various bodily functions are generally considered for extended therapy.

Q: Does Papaverine HCl affect blood sugar levels?

Blood sugar changes are not listed as a common side effect. However, a reported symptom in cases of very large oral overdose is hyperglycemia, or high blood sugar.

Q: Why is Papaverine sometimes compounded for localized use?

Compounding, which involves preparing specialized formulations, allows for localized forms to target a limited area of the body. The rationale for compounding is generally to create specialized, localized forms for targeted relief, which some suggest may lead to fewer systemic side effects compared to oral forms. Compounded preparations are not the officially approved forms of the drug.

Q: Can using Papaverine HCl cause changes in appetite?

Yes, official product labeling lists a change in appetite as a potential adverse reaction. One of the commonly reported gastrointestinal adverse reactions is loss of appetite.

Q: How does the route of administration change how Papaverine HCl works?

The route of administration affects the speed and duration of the drug's action. Parenteral (injected) administration is used to achieve an immediate effect, while oral capsules are designed to provide a sustained-release of the medicine over a longer period.

Q: Is Papaverine HCl a controlled substance in any countries?

In the United States, the drug is classified by the FDA as a non-narcotic opium alkaloid derivative. This classification indicates that it is not scheduled under the US federal controlled substances act.

Q: Is it true that Papaverine HCl was once used for heart rhythm problems?

Intravenous use is specifically contraindicated in patients with a severe heart rhythm disturbance called complete AV heart block because the drug has the potential to produce transient ectopic rhythms (short-term heart rhythm disturbances).

How should Papaverine HCl be stored and disposed of?

Storage and Disposal of Papaverine Hydrochloride

Papaverine HCl Injection must be stored at Controlled Room Temperature, specifically between 20 C to 25 C. The medication must be Protected From Light and stored in a tight, light-resistant container, often requiring that the vials be Retained In Carton Until Time Of Use. Additionally, the product must be kept out of the reach of children.

For disposal, the regulatory guidelines specify that the unused product and containers must be discarded in accordance with all local, regional, and national regulations. It is strictly required that the medication not be emptied into drains or otherwise released to the environment. Single-use vials are to be discarded after use.

Papaverine HCl